Can a cancer drug tame rare bleeding Disorder's heart complications?

This study looks at whether the drug bevacizumab can help people with a rare condition called hereditary hemorrhagic telangiectasia (HHT) who have severe liver problems leading to high heart output and possible heart failure. Researchers will check heart function before and after 6 months of treatment in about 111 participants from French HHT centers. The goal is to see if the drug improves heart function and to monitor for side effects.